Eosinophilia--A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis.
| Title: | Eosinophilia--A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis. |
|---|---|
| Authors: | Chiriac A; a Department of Dermato-Physiology , Apollonia University , Iasi , Romania .; b Department of Dermatology , Nicolina Medical Center , Iasi , Romania .; c 'P. Poni' Institute of Macromolecular Chemistry , Iasi , Romania .; Brzezinski P; d Department of Dermatology , 6th Military Support Unit , Ustka , Poland .; Stolnicu S; e Department of Pathology .; Podoleanu C; f Department of Cardiology .; Moldovan C; g Department of Histology , and.; Molnar C; h Department of Surgery , University of Medicine and Pharmacy of Targu Mures , Romania , and.; Taranu T; i Department of Dermatology , University of Medicine and Pharmacy 'Gr. T. Popa' Iasi , Romania. |
| Source: | The Journal of dermatological treatment [J Dermatolog Treat] 2016; Vol. 27 (2), pp. 110-3. Date of Electronic Publication: 2015 Sep 02. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Informa Healthcare; Original Publication: Houndmills, Basingstoke, Hampshire, UK : M. Dunitz and Macmillan Press, [c1989]- |
| MeSH Terms: | Adalimumab/*therapeutic use ; Eosinophilia/*chemically induced ; Psoriasis/*drug therapy ; Tumor Necrosis Factor-alpha/*antagonists & inhibitors; Adalimumab/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies |
| Abstract: | The current use of tumor necrosis factor (TNF)-alpha inhibitors in rheumatological, dermatological and gastroenterological diseases has increased considerably in recent years. Different reports have been communicated regarding specific risks and side effects during treatment with TNF-alpha inhibitors. Eosinophilia has been linked to TNF-alpha inhibitors by several recent reports, although it is not listed as a possible adverse reaction in the product information of the drug. The aim of the present study was to evaluate the eosinophil count in patients diagnosed with psoriasis and treated with adalimumab. Based on the results of the present study, eosinophilia remains a rare adverse reaction during psoriasis treatment with TNF-alpha antagonists. |
| Contributed Indexing: | Keywords: Adalimumab; adverse reaction; laboratory |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal, Humanized); 0 (Tumor Necrosis Factor-alpha); FYS6T7F842 (Adalimumab) |
| Entry Date(s): | Date Created: 20150822 Date Completed: 20160915 Latest Revision: 20220330 |
| Update Code: | 20260130 |
| DOI: | 10.3109/09546634.2015.1079299 |
| PMID: | 26292921 |
| Database: | MEDLINE |
Journal Article